High Tone Therapy for Chemotherapy Induced Neuropathy

Inclusion criteria: Patients with histologically verified colorectal cancer and adjuvant treatment with a platin derivate (e.g., cisplatin, oxaliplatin): This group was chosen due to relatively high risk of neuropathy due to this special therapeutic agent 1,9. Cumulative dose of at least 3 cycles Interval of 2 weeks since the last chemotherapeutic cycle in order to prevent false worsenings due to delayed neurotoxic effects Life expectancy of at least 3 months Stable medication (no changes of especially pain medication during the study) Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0-2 (that is, the capability to walk and to spend less than 50% of waking hours sitting or lying) Ability to walk (with or without aids) European Organisation for Research and Treatment of Cancer (EORTC) common toxicity criteria (CTC) peripheral sensory neuropathy grade 1 or 2 Intensity of paresthesias of 3/10 or higher on the Numeric Rating Scale (NRS) Exclusion criteria: Prevalent neuropathy of different etiology Serious central-neurological or psychiatric disorder that would interfer with a proper order of the study, according to the judgement of the investigators Epilepsy Minors or persons unable to give informed consent Current neurotoxic medication Implanted pacemakers or defibrillators Pregnancy Wounds in the area to be treated, acute local or systemic infection Peripheral arterial occlusive disease > grade 2